Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 7/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133078 | 0.90 | PDGFRB (0.40) | SLC40A1GLO1SLC22A12PDGFRBKDR | |
| SCHEMBL2138380 | 0.87 | SLC40A1 (0.40) | SLC40A1GLO1BRAFCKS1BSKP2 | |
| SCHEMBL2615622 | 0.85 | SLC40A1 (0.39) | SLC40A1GLO1BRAFCKS1BSKP2 | |
| SCHEMBL2133536 | 0.85 | KMT2A (0.46) | SLC40A1GLO1CYP3A4ALPLCKS1B | |
| SCHEMBL2138836 | 0.85 | TBXA2R (0.41) | SLC40A1GLO1CKS1BSKP2 | |
| SCHEMBL2135130 | 0.84 | ALPL (0.41) | ALPLCYP2C9 | |
| SCHEMBL2135919 | 0.84 | PARP14 (0.38) | SLC22A12 | |
| SCHEMBL2615613 | 0.83 | SLC40A1 (0.39) | SLC40A1GLO1CKS1BSKP2 | |
| SCHEMBL16239546 | 0.83 | USP2 (0.40) | SLC40A1GLO1CKS1BSKP2 | |
| SCHEMBL2133027 | 0.81 | F10 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630124-B1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | claimed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | claimed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | PRKAG1, PRKAB1, PRKAG2 | SLC40A1 3031/4885GLO1 1252/4885SLC22A12 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.